Business Wire

MA-VERACODE

Share
Veracode Research Reveals Government Applications at Heightened Risk of Cyber Attack: 59% Have Flaws Left Unfixed for More than a Year

Veracode, a global leader in application risk management, today released research revealing applications developed by public sector organizations have more security debt than those created by the private sector. Security debt, defined for this report as flaws that remain unfixed for longer than a year, exists in 59 percent of applications in the public sector, compared to the overall rate of 42 percent. The research analyzed public sector organizations in more than 25 countries across the globe.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240529282258/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Figure 2: Security Debt in Public Sector Applications (Graphic: Business Wire)

“Decades of accumulated security debt in unpatched software and poor security configurations, are in the applications that serve our government,” said Chris Eng, Chief Research Officer at Veracode. “Without a systematic and continuous approach to finding and fixing security flaws, the public sector is left dangerously exposed to attacks from hackers.”

Federal government systems are increasingly under cyberattack, as malicious criminals target public sector organizations with more damaging and disruptive techniques. In response, the federal government is enforcing a flurry of initiatives to strengthen cybersecurity, including efforts to reduce risk in the applications that serve the government. In March of 2024, the Cybersecurity and Infrastructure Security Agency (CISA) and the Office of Management and Budget (OMB) released the Secure Software Development Attestation Form to hold providers to the federal government accountable for insecure software.

Veracode researchers found that while slightly fewer public sector organizations (68 percent) have security debt than other industries (71 percent), they tend to accumulate more of it. Only three percent of applications are flaw-free, compared to six percent across other industries. Even more concerning, 40 percent of public sector entities have persistent, high-severity flaws that constitute ‘critical’ security debt, which would put the confidentiality, integrity, and availability of businesses at serious risk if exploited.

“The good news is that most organizations have the capacity to remediate all critical debt, but risk prioritization is key,” said Eng. “Two-thirds of all flaws in public sector organizations are either less than one year old or are not critical in severity. In addition, less than one percent of all flaws constitute critical security debt. By prioritizing that security debt with focused effort, organizations can achieve maximum risk reduction and then move to address non-critical flaws based on their risk tolerance and capabilities.”

According to the report, security debt in the public sector primarily affects first-party code (93 percent), but most of the critical security debt comes from third-party dependencies (55.5 percent). This reinforces the importance of the Open Source Security Software Initiative (OS3I), an inter-agency working group focused on ensuring open-source software is “as safe, secure and sustainable as it is open.” It also emphasizes the need for organizations to focus on both first- and third-party code to effectively reduce security debt.

The analysis further shows security debt in the public sector is primarily concentrated in older, larger applications (22 percent). This is especially true for critical security debt (30 percent), confirming a correlation between application age and the accumulation of security debt. Researchers also compared the security debt profile for different development languages and found that Java and .NET applications stand out as significant sources of debt in the public sector.

“The current state of software security in the public sector reinforces the importance of making secure by design a standard approach for the whole network connected world,” closed Eng. “We applaud CISA’s recent announcement of its Secure by Design Pledge and are proud to be one of the inaugural signatories. Our goal with this research is to further support our government and industry partners in promoting widespread adoption of these principles.”

The full State of Software Security Public Sector 2024 report is available to download on the Veracode website.

About the State of Software Security Report

The Veracode State of Software Security 2024 report analyzed data from large and small companies, commercial software suppliers, software outsourcers, and open-source projects. The research draws from more than a million (1,007,133) applications across all scan types, 1,553,022 dynamic analysis scans, and 11,429,365 static analysis scans. All those scans produced 96 million raw static findings, 4 million raw dynamic findings, and 12.2 million raw software composition analysis findings.

About Veracode

Veracode is a global leader in Application Risk Management for the AI era. Powered by trillions of lines of code scans and a proprietary AI-assisted remediation engine, the Veracode platform is trusted by organizations worldwide to build and maintain secure software from code creation to cloud deployment. Thousands of the world’s leading development and security teams use Veracode every second of every day to get accurate, actionable visibility of exploitable risk, achieve real-time vulnerability remediation, and reduce their security debt at scale. Veracode is a multi-award-winning company offering capabilities to secure the entire software development life cycle, including Veracode Fix, Static Analysis, Dynamic Analysis, Software Composition Analysis, Container Security, Application Security Posture Management, and Penetration Testing.

Learn more at www.veracode.com, on the Veracode blog, and on LinkedIn and X.

Copyright © 2024 Veracode, Inc. All rights reserved. Veracode is a registered trademark of Veracode, Inc. in the United States and may be registered in certain other jurisdictions. All other product names, brands or logos belong to their respective holders. All other trademarks cited herein are property of their respective owners.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240529282258/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Ant Group Unveils China’s First Multimodal AI Assistant with Code-Driven Outputs18.11.2025 09:05:00 CET | Press release

Ant Group today launched LingGuang, a next-generation multimodal AI assistant and the first of its kind in China that interacts with users through code-driven outputs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117438567/en/ Equipped with the capability to understand and produce language, image, voice and data, LingGuang delivers precise, structured responses to complex queries through 3D models, audio clips, charts, animations, interactive maps, and even immediately generated applications, in addition to traditional text-based conversation. Designed around three key features, LingGuang aims to make complex knowledge simpler and more intuitive, transforming how users access information and interact with AI tools. Fast Research: LingGuang responds to user questions or keywords with dynamic, multimodal content, making research on any topic clearer and more engaging. Its 3D digital modeling capability transcends traditio

SkySparc Appoints Oliver Bussmann as Chairman of the Board18.11.2025 09:00:00 CET | Press release

Appointment of industry veteran follows majority growth investment from Bregal Milestone SkySparc, a trusted global provider of digital transformation solutions for treasury and finance organizations, today announced the appointment of Oliver Bussmann as Chairman of the Board, following the closing of a majority growth investment from Bregal Milestone, a leading European software private equity firm. As former Global CIO at UBS and SAP, Bussmann has a proven track record of scaling B2B software and services across the Office of the CFO, Financial Services, RegTech, and WealthTech. Throughout his career, he has guided organizations through complex SaaS transitions, strategic M&A, and go-to-market acceleration – delivering multiple successful exits and sustained enterprise growth. Bussmann will help steer SkySparc’s technology and value-creation agenda, as Chairman, leveraging his network across financial services and technology to accelerate innovation, expand AI adoption, and drive lon

European Commission Grants Approval of Remsima™ IV Liquid Formulation, World’s First Liquid Formulation of IV Infliximab18.11.2025 08:23:00 CET | Press release

Remsima™ IV (intravenous) liquid formulation, the world’s first liquid formulation of IV infliximab has been approved by the European Commission (EC) for all previously approved indications for Remsima™ IV powder formulation1The approval is based on the comparability data between infliximab powder formulation and the liquid formulation2The new liquid formulation of infliximab, available in 100 mg and a newly introduced 350 mg presentation, eliminates the need for reconstitution and cuts drug preparation time by 51%, lowering preparation costs by 20%1,3Projected annual cost savings across seven European countries could reach up to €2.6 million, alongside significant improvements to workflow efficiency3 Celltrion, Inc. today announced that the European Commission (EC) has granted marketing authorization for Remsima™ IV (intravenous) liquid formulation, the world’s first liquid formulation of IV infliximab. Approved in 100 mg and 350 mg vials, the formulation is designed to streamline inf

Swiss-Based Debiopharm Seeks to Boost Innovation in Japanese Cancer Research Through the New "Ideal Japan” Program18.11.2025 08:00:00 CET | Press release

After 20 years of the prestigious JCA (Japanese Cancer Association) Mauvernay Award in Japan, Debiopharm is now transitioning its longstanding support for Japanese research to the new IDEAL Japan initiativeThe “Innovation Debiopharm Academia Life Science” (IDEAL) program is designed to financially and scientifically support academic research with the goal of accelerating the translation of innovation into novel therapies for patientsThe first IDEAL Japan agreement was signed with the National Cancer Center Japan Research Institute Laboratory of Genome Stability Maintenance to advance research in early-stage colon cancer Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company aiming to cure cancer and infectious diseases, is pleased to announce today the launch of the new IDEAL Japan initiative. This program was initiated to provide financial support to Japanese academic researchers in order to facilitate the transformation of academic innovation into novel therapeutic approa

Avanzanite Bioscience Secures €32M Series A Investment from MVM Partners18.11.2025 07:00:00 CET | Press release

MVM Partners joins as Avanzanite’s first institutional investor. Funding will scale Avanzanite’s existing infrastructure in all 32 countries in Europe, propel current launches, and support further product alliances and acquisitions. In just 3 years, Avanzanite has entered 3 strategic alliances and actively launched 3 rare disease medicines. Avanzanite’s Q3 2025 revenue tripled year-on-year and climbed over 20% quarter-on-quarter. Avanzanite is a unique, fully integrated partner for biotech and pharma innovators seeking to market and distribute their rare disease medicines in Europe. A new pan-European standard is being set for orphan medicine launches and patient access, with no one left behind. Avanzanite Bioscience B.V. (Avanzanite), a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today announced a €32 million Series A growth investment from MVM Partners (MVM), a leading global life-science private equity firm. This press release

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye